About
George Johnson is an Associate Professor in Biomedical Sciences at Swansea University's Faculty of Medicine, Health and Life Science. He serves as Director of Employability and Entrepreneurship for the Medical School and teaches on the Genetics Degree programme. His research is conducted within the DNA damage group (in vitro Toxicology group) at the Institute of Life Science.
Johnson's research focuses on genetic toxicology, human health risk assessment, dose response modeling, and imaging flow cytometry. His work bridges fundamental research in DNA damage mechanisms with practical applications in pharmaceutical risk assessment, particularly regarding N-nitrosamine impurities. He has developed advanced methodologies for benchmark dose analysis and quantitative risk assessment that have been adopted by regulatory agencies worldwide.
His publication record shows a strong trend toward increasingly sophisticated quantitative approaches to genetic toxicology, with recent work focusing on N-nitrosamine risk assessment, imaging flow cytometry applications, and development of frameworks for translating in vitro genotoxicity data to in vivo risk predictions. The 2023-2025 publications demonstrate growing emphasis on computational modeling and quantitative risk assessment methodologies.
- UKEMS Young Scientist Award (2012)
- Fellow of the Higher Education Academy (2013)
- British & European Registered Toxicologist (2014)
- EEM(G)S Young Scientist Award (2014)
- Elected President of EEMGS society (2019)
Johnson actively supervises postgraduate research, with current projects focusing on deep learning applications for genotoxicity assessment, mutagenicity of compounds using benchmark dose analysis, and validation of mutagenicity assays for nitrosamine assessment. He has led numerous international collaborations with organizations including US-FDA-NCTR, Health Canada, RIVM-Netherlands, and major pharmaceutical companies. As a consultant through Swansea Innovations, he works with pharmaceutical, food additive, and chemical industries on deriving point of departure metrics for human health risk assessments.
He is a steering member and co-chair of subgroups for the Health and Environmental Sciences Institute (HESI) Genetic Toxicology Technical Committee, providing an international forum for advancing understanding of scientific issues related to human health, toxicology, and risk assessment.
